NovoCure Limited (NASDAQ:NVCR) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the NovoCure Q2 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Novocure Ltd (NVCR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 1,319,400 | $22,601,322 | -9% | 0.05% |
| 2. | Millennium Management Israel Englander | 1,205,892 | $20,656,930 | -2% | 0% |
| 3. | Renaissance Technologies Jim Simons | 760,175 | $13,021,798 | +172% | 0.02% |
| 4. | D E Shaw D. E. Shaw | 699,294 | $11,978,906 | -27% | 0.01% |
| 5. | Coatue Management Philippe Laffont | 608,672 | $10,426,551 | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $96.50 | 104 | Officer, Director | 13,276 | 2021-11-26 | Filing | |
| $103.37 | 1,000 | Officer, Director | 13,172 | 2021-11-26 | Filing | |
| $102.36 | 3,870 | Officer, Director | 12,172 | 2021-11-26 | Filing | |
| $85.01 | 4,200 | Officer | 98,786 | 2020-09-02 | Filing | |
| $6.93 | 125,000 | Director | 6,125,000 | 2017-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.14 | 688 | 219,179 | 2024-08-02 | Filing | ||
| $23.89 | 964 | 164,833 | 2024-06-04 | Filing | ||
| $23.89 | 964 | 2,964 | 2024-06-04 | Filing | ||
| $23.89 | 964 | 78,175 | 2024-06-04 | Filing | ||
| $16.01 | 1,217 | 251,235 | 2024-03-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,962,767 | $238,324,102 | 0.01% | |
| 2. | 9,759,098 | $145,703,333 | 0% | |
| 3. | 8,861,871 | $132,307,734 | 0.02% | |
| 4. | 8,792,035 | $131,265,083 | 0% | |
| 5. | 4,840,141 | $72,263,305 | 0.05% |
News See All
NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript
NovoCure Limited beats earnings expectations. Reported EPS is $-0.36134, expectations were $-0.43.
Aggressive Stock Portfolio: 5 Stocks Picked by Analysts
In this article, we will take a look at the aggressive stock portfolio: 5 stocks picked by analysts.
NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the NovoCure Q4 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
15 Best Falling Stocks To Buy Now
In this piece, we will take a look at the 15 best falling stocks to buy now.
11 Best Undervalued UK Stocks To Buy Now
In this piece, we will take a look at the 11 best undervalued U.K. stocks to buy now.
NovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call Transcript
Operator: Welcome to the NovoCure Q3 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
Should You Hold NovoCure Limited (NVCR)?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Strategy” second quarter 2023 investor letter. A copy of the same can be downloaded here.
5 Worst Performing Healthcare Stocks in 2023
In this article, we discuss 5 worst performing healthcare stocks in 2023.
5 Oversold Healthcare Stocks to Buy
Root, Switzerland-based NovoCure Limited (NASDAQ:NVCR) is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization...
Billionaire Hedge Funds
